Skip to main content
. Author manuscript; available in PMC: 2018 Jun 20.
Published in final edited form as: J Innate Immun. 2008 Oct 1;1(4):358–365. doi: 10.1159/000161070

Fig. 5.

Fig. 5

Anti-LOX-1 prevents LPS-induced lung NF-κB activity and ICAM-1 expression. At 6 h after LPS challenge, anti-LOX-1 (LOX-1AB/LPS) inhibited LPS-induced NF-κB activity (A) and ICAM-1 expression (B) in mouse lung compared with mice treated with LPS alone (LPS) or pretreated with control IgG (NIgG/LPS). Anti-LOX-1 showed no effects on LOX-1 expression. The results are representative of 3 independent experiments. Asterisk indicates a statistical difference between two groups (n = 12 for each group, p < 0.05).